Logo image of CLNN

CLENE INC (CLNN) Stock Price, Quote, News and Overview

NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD

3.01  -0.16 (-5.05%)

CLNN Quote, Performance and Key Statistics

CLENE INC

NASDAQ:CLNN (4/25/2025, 10:38:58 AM)

3.01

-0.16 (-5.05%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High9.2
52 Week Low2.57
Market Cap25.98M
Shares8.63M
Float5.46M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/bmo
IPO08-27 2018-08-27


CLNN short term performance overview.The bars show the price performance of CLNN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

CLNN long term performance overview.The bars show the price performance of CLNN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CLNN is 3.01 USD. In the past month the price decreased by -10.45%. In the past year, price decreased by -53.37%.

CLENE INC / CLNN Daily stock chart

CLNN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.99 321.97B
AMGN AMGEN INC 14.09 150.13B
GILD GILEAD SCIENCES INC 13.29 128.22B
VRTX VERTEX PHARMACEUTICALS INC 1690.03 126.00B
REGN REGENERON PHARMACEUTICALS 13.01 64.90B
ARGX ARGENX SE - ADR 326.12 37.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.57B
BNTX BIONTECH SE-ADR N/A 28.31B
ONC BEIGENE LTD-ADR N/A 26.72B
SMMT SUMMIT THERAPEUTICS INC N/A 25.29B
NTRA NATERA INC N/A 20.75B
BIIB BIOGEN INC 7.21 17.38B

About CLNN

Company Profile

CLNN logo image Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 82 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.

Company Info

CLENE INC

6550 South Millrock Drive, Suite G50

Salt Lake City UTAH 84121 US

CEO: Robert Etherington

Employees: 84

Company Website: https://clene.com/

Investor Relations: http://invest.clene.com/

Phone: 18016769695

CLENE INC / CLNN FAQ

What is the stock price of CLENE INC today?

The current stock price of CLNN is 3.01 USD. The price decreased by -5.05% in the last trading session.


What is the ticker symbol for CLENE INC stock?

The exchange symbol of CLENE INC is CLNN and it is listed on the Nasdaq exchange.


On which exchange is CLNN stock listed?

CLNN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CLENE INC stock?

12 analysts have analysed CLNN and the average price target is 46.07 USD. This implies a price increase of 1430.56% is expected in the next year compared to the current price of 3.01. Check the CLENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CLENE INC worth?

CLENE INC (CLNN) has a market capitalization of 25.98M USD. This makes CLNN a Nano Cap stock.


How many employees does CLENE INC have?

CLENE INC (CLNN) currently has 84 employees.


What are the support and resistance levels for CLENE INC (CLNN) stock?

CLENE INC (CLNN) has a support level at 3.02 and a resistance level at 3.75. Check the full technical report for a detailed analysis of CLNN support and resistance levels.


Is CLENE INC (CLNN) expected to grow?

The Revenue of CLENE INC (CLNN) is expected to decline by -17.54% in the next year. Check the estimates tab for more information on the CLNN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CLENE INC (CLNN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CLENE INC (CLNN) stock pay dividends?

CLNN does not pay a dividend.


When does CLENE INC (CLNN) report earnings?

CLENE INC (CLNN) will report earnings on 2025-05-13, before the market open.


What is the Price/Earnings (PE) ratio of CLENE INC (CLNN)?

CLENE INC (CLNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.94).


What is the Short Interest ratio of CLENE INC (CLNN) stock?

The outstanding short interest for CLENE INC (CLNN) is 1.58% of its float. Check the ownership tab for more information on the CLNN short interest.


CLNN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CLNN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CLNN. Both the profitability and financial health of CLNN have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CLNN Financial Highlights

Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -5.94. The EPS increased by 42.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -144.13%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-55%
Sales Q2Q%-46.47%
EPS 1Y (TTM)42.88%
Revenue 1Y (TTM)-48.18%

CLNN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CLNN. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 43.08% and a revenue growth -17.54% for CLNN


Ownership
Inst Owners13.69%
Ins Owners25.17%
Short Float %1.58%
Short Ratio1.54
Analysts
Analysts81.67
Price Target46.07 (1430.56%)
EPS Next Y43.08%
Revenue Next Year-17.54%